Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Annexon studies ANX-005 for Huntington's disease in phase II

Sep. 29, 2020

Popular opinion correct on fear, anxiety

Sep. 28, 2020

FDA clears IND application for ANK-700

Sep. 28, 2020

Phase II study of semorinemab in early Alzheimer's misses key efficacy endpoints

Sep. 25, 2020

Nocion Therapeutics presents new SCN9A blockers

Sep. 25, 2020

If a tree stings in the wood, it's with a peptide

Sep. 25, 2020

Vaccinex reports topline phase II data on pepinemab in Huntington's disease

Sep. 23, 2020

P2X4R inhibition reduces proinflammatory myeloid cells, offering neuroprotection after stroke

Sep. 23, 2020

Kemp Proteins to provide assay development for first-in-class chronic SCI therapy, AXER-204

Sep. 23, 2020

Glial metabolism affects neural recovery

Sep. 23, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...